SCHEMBL5134964

SCHEMBL5134964

CCCCN(Cc1c(F)cccc1Cl)Cc1c(-c2ccccc2)nc(-c2ccccc2)n1CC

nearest known ligand 0.40

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 3/20 0.40
CRHR1 P34998 2/20 0.36
ALDH1A1 P00352 1/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
BCL2L1 Q07817 1/20 0.36
BAK1 Q16611 1/20 0.36
GAA P10253 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
LMNA P02545 1/20 0.34
HDAC1 Q13547 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5134752 0.93 C5AR1 (0.39) P2RX7CRHR1ALDH1A1POLBMAPT
SCHEMBL5072419 0.93 CRHR1 (0.36) P2RX7CRHR1ALDH1A1POLBMAPT
SCHEMBL5070038 0.93 P2RX7 (0.43) P2RX7CRHR1ALDH1A1HDAC1
SCHEMBL5135270 0.93 KDM4E (0.39) P2RX7CRHR1ALDH1A1HDAC1
SCHEMBL5136139 0.93 TSHR (0.37) CRHR1ALDH1A1POLBMAPTMEN1
SCHEMBL5137176 0.90 C5AR1 (0.37) CRHR1ALDH1A1MAPT
SCHEMBL5074878 0.86 TSHR (0.42) CRHR1ALDH1A1HDAC1
SCHEMBL5137873 0.86 KDM4E (0.38) CRHR1ALDH1A1MEN1KMT2AHDAC1
SCHEMBL5135784 0.86 C5AR1 (0.38) P2RX7CRHR1ALDH1A1HDAC1
SCHEMBL5134866 0.86 TSHR (0.42) P2RX7CRHR1ALDH1A1HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed